Results 201 to 208 of about 4,378 (208)

79P: Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer

Journal of Thoracic Oncology
V. M. Garcia, A. Drilon, S. Kummar, J.J. Lin, D. Tan, D.T. Rieke, B. Dubashi, H. Kunhiparambath, D. Burcoveanu, N. Neu, C. Mussi, C. Qi   +11 more
semanticscholar   +1 more source

Dactinomycin/larotrectinib

Reactions Weekly
openaire   +1 more source

Adjuvant Larotrectinib in a Resected Secretory Carcinoma-Like Lung Adenocarcinoma harboring EML4-NTRK3 Fusion

JTO Clinical and Research Reports
V. C. Cordeiro de Lima
semanticscholar   +1 more source

HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

Value in Health
Noman Paracha, Jamie Grossman, Sarah Ba, Federico Manevy   +3 more
semanticscholar   +1 more source

Summary of opinion: Vitrakvi,larotrectinib

Case Medical Research, 2019
openaire   +1 more source

Larotrectinib in TRK fusion-positive cancers

The Lancet Oncology, 2018
openaire   +1 more source

Larotrectinib/lenvatinib/selitrectinib

Reactions Weekly
openaire   +1 more source

Larotrectinib - Ein "Breitband"-Krebstherapeutikum

Österreichische Apothekerzeitung, 2018
openaire   +1 more source